The primary objective of this study is to determine if creatine supplementation improves acoustic, auditory perceptual, physiologic, and patient-reported outcome measures in patients over 65 years of age. In the study, 20 participants will be enrolled and randomly assigned to receive either creatine or placebo.

开始日期2025-05-01

申办/合作机构

NYU Langone Health

DRKS00035357

/ RecruitingN/AIIT

Fostering optimal recovery through creatine supplementation and electrical muscular stimulation - FORCE

开始日期2025-03-01

申办/合作机构

University Hospital of Ludwig-Maximilians-University

NCT06675708

/ Enrolling by invitationN/AIIT

Study of the Effectiveness of Creatine on Pain, Fatigue, and Muscle Architectural Variables in Patients Witg Fibromyalgia.

Creatine, a non-protein organic amino acid, is synthesized from arginine, glycine, and methionine. The use of creatine has been shown to be effective in healthy subjects, providing benefits primarily in terms of strength, which has been the main factor studied. In patients with various conditions, including pain, creatine supplementation has demonstrated a reduction in pain and even cognitive improvements.
Due to creatine's general improvement in muscular endurance and fatigue.

开始日期2025-02-12

申办/合作机构-

100 项与 Creatine monohydrate 相关的临床结果

登录后查看更多信息

100 项与 Creatine monohydrate 相关的转化医学

登录后查看更多信息

100 项与 Creatine monohydrate 相关的专利（医药）

登录后查看更多信息

18,580

项与 Creatine monohydrate 相关的文献（医药）

2025-12-31·Journal of the International Society of Sports Nutrition

Part II. Common questions and misconceptions about creatine supplementation: what does the scientific evidence really show?

Review

作者: Tarnopolsky, Mark A. ; Ellery, Stacey J. ; Antonio, Jose ; Gualano, Bruno ; Smith-Ryan, Abbie E. ; Forbes, Scott C. ; Kerksick, Chad ; Roschel, Hamilton ; Roberts, Michael D. ; VanDusseldorp, Trisha A. ; Candow, Darren G. ; Ziegenfuss, Tim N. ; Ostojic, Sergej M. ; Willoughby, Darryn S. ; Jagim, Andrew R. ; Stout, Jeffrey R. ; Rawson, Eric S. ; Brown, Ann F. ; Kreider, Richard B. ; Chilibeck, Philip D.

Creatine monohydrate supplementation (CrM) is a safe and effective intervention for improving certain aspects of sport, exercise performance, and health across the lifespan. Despite its evidence-based pedigree, several questions and misconceptions about CrM remain. To initially address some of these concerns, our group published a narrative review in 2021 discussing the scientific evidence as to whether CrM leads to water retention and fat accumulation, is a steroid, causes hair loss, dehydration or muscle cramping, adversely affects renal and liver function, and if CrM is safe and/or effective for children, adolescents, biological females, and older adults. As a follow-up, the purpose of this paper is to evaluate additional questions and misconceptions about CrM. These include but are not limited to: 1. Can CrM provide muscle benefits without exercise? 2. Does the timing of CrM really matter? 3. Does the addition of other compounds with CrM enhance its effectiveness? 4. Does CrM and caffeine oppose each other? 5. Does CrM increase the rates of muscle protein synthesis or breakdown? 6. Is CrM an anti-inflammatory intervention? 7. Can CrM increase recovery following injury, surgery, and/or immobilization? 8. Does CrM cause cancer? 9. Will CrM increase urine production? 10. Does CrM influence blood pressure? 11. Is CrM safe to consume during pregnancy? 12. Does CrM enhance performance in adolescents? 13. Does CrM adversely affect male fertility? 14. Does the brain require a higher dose of CrM than skeletal muscle? 15. Can CrM attenuate symptoms of sleep deprivation? 16. Will CrM reduce the severity of and/or improve recovery from traumatic brain injury? Similar to our 2021 paper, an international team of creatine research experts was formed to perform a narrative review of the literature regarding CrM to formulate evidence-based responses to the aforementioned misconceptions involving CrM.

2025-12-31·Journal of the International Society of Sports Nutrition

Sport supplementation in competitive swimmers: a systematic review with meta-analysis

Review

作者: Domínguez, Raúl ; Rico, Esteban ; López-León, Inmaculada ; Sánchez-Oliver, Antonio J. ; Pecci, Javier ; Sánchez-Gómez, Ángela ; Moreno-Lara, Javier

BACKGROUND:

Competitive swimmers have a high prevalence of sports supplement (SS) consumption. However, only a few SS are scientifically proven to be safe, effective, and legal. Therefore, before incorporating supplements to enhance performance and health in competitive swimming, it is crucial to conduct an analysis and review to assess their effects. The objective of this study was to analyze the demonstrated effects of SS, as reported in published studies, on the swimming performance of competitive swimmers.

METHODS:

Following PRISMA guidelines, a systematic search was conducted across six databases for the selection of studies included in this review. Studies that analyzed the effects of sports supplementation compared to placebo were included and subjected to meta-analysis.

RESULTS:

This revision included 23 studies, 16 of them (69.6%) qualified as excellent and 7 (30.4%) as good at the methodological level based on the punctuation in the PEDro scale. The systematic review included 422 swimmers (61.8% male, 38.2% female), with distances assessed ranging from 50 m to 800 m, including studies employing interval procedures. Creatine showed a significant effect (ES = -0.46; 95% CIs = -0.75 to -0.17, p = 0.002; I² = 11%) on swimming performance, while the rest of the analyzed supplements did not show significant effects (all p > 0.05).

CONCLUSIONS:

Creatine supplementation demonstrated ergogenic benefits for competitive swimmers, although the evidence supporting the use of this supplement is still limited. Sodium bicarbonate and β-alanine may enhance performance in distances with higher glycolytic demands, while caffeine is effective at dosages of 3-6 mg/kg administered 60 min before exercise. Further research is needed to confirm the potential ergogenic effects of other supplements, such as beetroot juice.

2025-12-31·Journal of the International Society of Sports Nutrition

International society of sports nutrition position stand: nutrition and weight cut strategies for mixed martial arts and other combat sports

Review

作者: Algieri, Chris ; Jeffery, Aaron ; Campbell, Bill I. ; Stull, Charles ; Kreider, Richard B. ; Tartar, Jaime ; French, Duncan N. ; Kerksick, Chad M. ; Stout, Jeffery R. ; Galpin, Andrew J. ; Ricci, Anthony A. ; Johnson, Sarah ; Antonio, Jose ; Kalman, Douglas ; La Bounty, Paul ; Fukuda, David H. ; Peacock, Corey A. ; Evans, Cassandra

Following an extensive literature review, the International Society of Sports Nutrition (ISSN) has developed an official position on nutritional and weight cut strategies for combat sports. The type of combat sport, length of the fight camp, and time between weigh-in and competition are factors influencing nutritional and weight cut strategies. The following 16 points constitute the Position Statement of the Society; the Research Committee has approved them. 1. Combat sports have differing weight categories, official weigh-in times, and competition frequencies, influencing the nutritional and weight cut strategies for training and competition. 2. As the duration of a combat match increases, >4 min, contribution of the aerobic system can rise to >70%, yet anaerobic alactic pathways and anaerobic glycolytic pathways support high-output bursts. 3. During the off camp/general preparation phase, athletes should maintain a weight ranging 12% to 15% above the weight division requirement. 4. Supplements including creatine, beta-alanine, beta-hydroxy-beta-methylbutyrate, and caffeine have been shown to enhance performance and/or recovery during preparation phases, competition, and post-competition. 5. During fight camp, strategic decreases in calorie intake are necessary for an efficient longitudinal weight descent. Individual caloric needs can be determined using indirect calorimetry or validated equations such as Mifflin St. Jeor or Cunningham. 6. Protein should be prioritized during longitudinal weight descents to preserve lean body mass, and the timely delivery of carbohydrates supports training demands. Macronutrients should not drop below the following: carbohydrates 3.0-4.0 g/kg, protein 1.2-2.0 g/kg, and fat 0.5 to 1.0 g/kg/day. 7. Suitable losses in body mass range from 6.7% at 72 h, 5.7% at 48 h, and 4.4% at 24 h, prior to weigh-in. 8. Sodium restriction and water loading are effective for inducing polyuria and acute water loss. 9. During fight week, water-bound glycogen stores can be depleted through exercise and carbohydrate restriction, facilitating a 1% to 2% loss in body mass, with equivalent losses from a low-fiber intake of <10 g/day for 4 days. 10. During fight week, acute water loss strategies, including sauna, hot water immersion, and mummy wraps, can be used effectively with appropriate supervision (optimally ~2-4% of body mass within 24 h of weigh-in). 11. Post-weigh-in, rapid weight gain strategies are utilized to recover lost body fluid/mass before competition with the intent of gaining a competitive advantage. 12. Oral rehydration solutions (1 to 1.5 liters/h) combined with a sodium range of 50-90 mmol/dL should take precedence immediately post-weigh-in. 13. Fast-acting carbohydrates at a tolerable rate of ≤ 60 g/h should follow oral rehydration solutions. Post weigh-in intake of fiber should be limited to avoid gastrointestinal distress. 14. Post-weigh-in carbohydrate intake at 8-12 g/kg may be appropriate for combat athletes that undertook significant glycogen depletion strategies during fight week. About 4-7 g/kg may be suitable for modest carbohydrate restriction. 15. Post weigh-in, rehydration/refueling protocols should aim to regain ≥10% of body mass to mitigate declines in performance and the negative effects of rapid weight loss. 16. The long-term effects of frequent weight cuts on health and performance are unknown, necessitating further research.

项与 Creatine monohydrate 相关的新闻（医药）

2025-05-08

·健识局

百济神州一季度盈利！而且还干成一件大事

百济神州说话算数，在今年第一季度实现了盈利。5月7日，百济神州港股、美股、A股三地同时发布的2025年第一季度财报透露的信息：公司总营收达到80.48亿元，同期相比增长了50.2%；利润总额比去年同期多了近20亿元，由亏转盈。公司在美国通用会计准则下，首次实现季度盈利。百济神州的核心产品泽布替尼、替雷利珠单抗的销售额暴涨，对业绩贡献功不可没。今年一季度，泽布替尼这款“BTK明星产品”全球销售额达56.92亿元。在美国市场表现尤为出色，泽布替尼的销售额超越强生和艾伯维开发的伊布替尼，成为美国第一；另一款重点产品PD-1替雷利珠单抗销售额12.45亿元，和其他PD-1产品拉开了差距。财报中，百济神州年初确定了“352亿-381亿”的2025年全年总收入指引。第一季度，百济神州重申该目标，并预计2025年全年经营利润为正且经营活动产生现金流为正。美国份额第一，泽布替尼实现超越在百济神州之前，国内还没有一家药企的创新产品能做到在美国市场和国际药企抢地盘。去年第四季度，泽布替尼在美国的销售额首次超越阿斯利康的阿可替尼，成为BTK行业第二。今年一季度，泽布替尼在美国市场又给了一大惊喜：超越了伊布替尼，这是创新药行业的标志性事件。从时间线来看，百济神州BTK抑制剂超越伊布替尼是早晚的事。泽布替尼从设计之初就锚定了艾伯维、阿斯利康等巨头的“腹地”慢性淋巴细胞白血病（CLL）。美国国家癌症研究所最新数据显示，CLL是西方人中最常见的白血病类型，是BTK抑制剂70%份额的核心战场。百济神州在2020年启动泽布替尼与伊布替尼的“头对头”全球III期试验，最终在2022年证明无进展生存期（PFS）和总缓解率(ORR)方面对比伊布替尼具备优效性，且表现出更具优势的心脏功能相关的安全性特征。在那之后，泽布替尼在海外市场快速放量，至今没看到放缓的势头，而且主要在新增处方上获得很大的份额。2023年1月，泽布替尼CLL适应症获FDA完全批准，当年第三季度占到新增处方量的25%；2024年第四季度，泽布替尼CLL新增处方量已经达到美国市场第一。早期慢淋的中位生存期可能达到10年之久，因此，获得更多新患处方，意味着将伴随患者很长的用药周期。在美国市场上，泽布替尼从新患者入手，花了两年左右时间就实现了销售额超越。一季度财报显示，泽布替尼美国市场销售额达40.41亿元人民币，并且增长势头冲劲十足，与去年同比增长61.9%；阿可替尼总量增长潜力不足；伊布替尼因为新患的流失，从去年开始一直处于销售萎缩状态，今年一季度美国市场销售又同比下跌了13%。去年，艾伯维向百济神州发起了专利诉讼，试图阻碍百济神州在美国市场上的凌厉攻势。今年4月29日，美国专利商标局宣布，艾伯维关于泽布替尼的803专利授权案败诉。泽布替尼在美国市场的销售将不再掣肘。从目前来看，泽布替尼“第一交椅”的位置会十分稳当，因为除了美国以外，泽布替尼在欧洲也打开了局面，一季度销售额同比增长75.4%；中国市场销售额为5.90亿元，同比增长43.1%，仍然保持领先地位。规模效益突显，具备持续盈利潜力泽布替尼海外市场的创新价值的高速释放，从侧面证明了百济神州自身愈发强大的战略实力。“2025年经营利润回正”就是百济神州为投资者许下的承诺。但这不是没有难度：想像其他国际药企一样，百济神州最紧要的是既能找到新的创新增长点，又得抗住资金支出压力。从一季报表现来看，百济神州正在有条不紊的兑现承诺。今年一季度，百济神州的研发投入小幅上升，重点投在前景更好的管线上，基本围绕泽布替尼、潜在“同类最佳”BCL2抑制剂索托拉克，以及潜在同类首创、同类最佳BTK降解剂BGB-16673，在血液肿瘤适应症的单药或联用使用，以及替雷利珠单抗等大品种、大适应症开展。在此基础上，公司临床研发效率更高了，几乎和主要跨国药企并排的研发路径走，从临床早期就向国际接轨，比如用CDK4与辉瑞拼速度疗效；B7H4 ADC也紧跟阿斯利康、GSK的速度。最重要的是，在产品之外，百济神州也能和跨国大药企上桌过几招了。在欧美市场，百济神州已经自建了本土商业化团队，深入渗透社区诊所网络，与当地药企“肉搏”。如今，销售费用率已经趋于平稳，目前已经降到了40%左右。在收入高速增长的背景下，销售管理费用同比仅增加7%。这说明，百济神州迈过了规模经济门槛，投入带来的效益正在逐步放大。国际化是百济神州坚定不移的市场开拓方向，替雷利珠单抗的主要战场也逐渐从国内走向全球，2025年，百济还将启动在美欧日等多个国家的新适应症提交，增加海外放量。公司还基本完成了具备跨国大药企标准的生产端的前期铺陈。去年7月，百济神州在新泽西州霍普韦尔的生产基地和临床研发中心已投入使用。该工厂每年可生产约200万瓶制剂，将助力百济神州自有的生物制剂生产和ADC生产能力延伸，包括替雷利珠单抗、21个临床阶段候选药物和7个临床前生物制剂产品等，提供全球化生产供应便利。财报中，百济神州联合创始人、董事长兼首席执行官欧雷强表示：“公司启用新英文名称BeOne Medicines，并已经将注册地迁至瑞士，公司正朝着成为全球最具影响力的肿瘤创新公司之一迈进。”目的地，就是“更深”的全球医药市场。撰稿丨苗苗编辑丨江芸贾亭运营｜李木子声明：健识局原创内容，未经许可请勿转载独家：信达生物重磅药品降价25%，确认参加医保谈判药店巨头计划套现4亿元新事丨2025年Q1，新的全球“药王”诞生

财报临床3期医药出海

2025-05-06

·生物世界

Cell Discovery：于杰团队揭示肌酸转运蛋白CRT的底物识别和抑制机制

编辑丨王多鱼排版丨水成文肌酸（creatine）作为人体能量代谢的核心分子，在肌肉和脑组织中发挥着“能量缓冲剂”的关键作用。特别是在神经元高强度工作时，它能快速补充 ATP，确保大脑功能的正常运转。肌酸转运蛋白 CRT（SLC6A8）负责将肌酸转运至细胞内，以满足组织的高能量需求。CRT 的遗传突变会导致 X 连锁肌酸转运蛋白缺陷（CTD），其特征是脑肌酸缺乏，临床表现包括严重智力障碍、癫痫、自闭症、发育迟缓和运动功能障碍等。目前，该疾病尚缺乏有效的治疗手段。值得注意的是，处于II期临床试验的化合物 RGX-202，正是通过竞争性抑制 CRT 的肌酸转运功能，有效诱导肿瘤细胞凋亡并抑制结直肠癌的生长。2025 年 5 月 5 日，中国科学院上海有机化学研究所生物与化学交叉研究中心于杰课题组与合作者在 Cell Discovery 期刊发表了题为：Transport and inhibition mechanisms of human creatine transporter 的研究论文。该研究首次报道了人源 CRT 蛋白在 apo 状态、底物 creatine 结合状态以及抑制剂 RGX-202 结合状态下的冷冻电镜结构。通过结合分子动力学模拟和功能实验，研究团队阐明了 CRT 识别底物和抑制剂的分子机制，并利用荧光显微镜技术深入探究了致病突变对 CRT 功能及细胞定位的影响。基于解析的 creatine 和 RGX-202 结合结构，研究团队提出：creatine 首先以向外开放的构象结合到中心位点，在 Na+ 和 Cl- 的参与下发生构象变化，转变为向内封闭的状态暴露于细胞质侧，随后与 Na+ 一起以内向开放的构象释放到细胞质中。值得注意的是，Cl- 在整个过程中保持在其保守位置而不被释放。而抑制剂 RGX-202 则通过直接竞争 creatine 的结合位点来抑制 CRT 功能（图1）。图1. CRT识别底物creatine和抑制剂RGX-202的分子机制该研究首次在原子层面阐明了 CRT 的底物识别和抑制的分子机制，为未来开发针对 CTD 的治疗药物提供了重要的理论依据和结构基础。中国科学院上海有机化学研究所生物与化学交叉研究中心博士研究生陈佳慧、张一敏，北京大学定量生物学中心陈楠浩博士为论文共同第一作者。中国科学院上海有机化学研究所生物与化学交叉研究中心于杰研究员和上海科技大学盖景鹏教授为论文共同通讯作者。该工作得到了上海市基础研究、上海市老龄化研究重点实验室和上海浦江计划的资助。论文链接：https://www.nature.com/articles/s41421-025-00801-4设置星标，不错过精彩推文开放转载欢迎转发到朋友圈和微信群微信加群为促进前沿研究的传播和交流，我们组建了多个专业交流群，长按下方二维码，即可添加小编微信进群，由于申请人数较多，添加微信时请备注：学校/专业/姓名，如果是PI/教授，还请注明。点在看，传递你的品味

临床1期

2025-04-08

·ioncology

大咖辩论：双特异性抗体会取代PD-(L)1抑制剂吗？丨IASLC肺癌靶向治疗会议

点击蓝字关注我们自2015年FDA首次批准纳武利尤单抗治疗晚期非小细胞肺癌（NSCLC）以来，临床医生已见证了使用抗PD-(L)1药物在一线和二线治疗中抑制癌细胞使总生存（OS）有所提高。[1]这十年的统治地位是否即将结束？双特异性抗体是否会取代PD-(L)1药物成为肺癌免疫治疗的主力？在2月20日举行的国际肺癌研究协会（IASLC）肺癌靶向治疗会议上，来自加州大学戴维斯分校的Jonathan W. Riess教授与密歇根大学的Greg Kalemkerian教授就此展开精彩正反辩论。▲Jonathan Riess, MD▼Greg Kalemkerian, MD正方：双特异性抗体即将加冕免疫治疗王冠Dr. Riess阐述三个核心论点捍卫其立场：1.双特异性抗体可靶向癌症免疫循环（cancer immunity cycle）的多个组成部分（包括阻断PD-1/PD-L1）双特异性抗体具有独特的能力，可以对一系列刺激/抑制免疫信号进行组合攻击，包括阻断免疫检查点、共刺激激活免疫细胞以及与细胞因子和炎症因子结合。图1. 双特异性抗体的特点2.作用机制的优势增强，例如产生协同结合（cooperative binding）双特异性抗体已显示出机制优势，例如协同结合。PD-1/VEGF双抗依沃西单抗的研究中就观察到这种机制优势。依沃西单抗与VEGF的协同结合可使PD-1亲和力（PD-1 affinity）增加18倍以上，而依沃西单抗与PD-1的协同结合可使VEGF亲和力增加4倍以上。[2]图2. 依沃西单抗的协同结合活性3.试验初始数据有前景随机III期头对头研究HARMONi-2显示，在PD-L1阳性NSCLC患者中，依沃西单抗相比帕博利珠单抗可显著延长无进展生存期（PFS），差异具有统计学意义，且获益在PD-L1表达高和PD-L1表达低的患者中均可见。[3]在EGFR突变NSCLC患者中，双特异性抗体的初步研究“非常有希望”。双特异性抗体（如volrustomig）在较难治疗的PD-L1阴性人群中具有良好的PFS数据。[4]反方：双抗尚难撼动PD-(L)1基石地位Dr. Kalemkerian从不同的角度探讨了这个问题，反驳了一系列他认为“未经证实”的关于双特异性抗体的假设。有人提出“双特异性抗体比联合疗法更好，已有初步数据和生物学原理证实”。他认为这些论点需要澄清，这一问题的关键在于“双特异性免疫靶向治疗是否比免疫检查点抑制剂单药治疗更能改善生存。”Dr. Kalemkerian通过展示一系列不成功的研究（涉及7,000多名患者）反驳了Dr. Riess的演讲。这些研究并未证明在抗PD-1/PD-L1疗法中添加其他免疫检查点抑制剂或血管内皮生长因子（VEGF）靶向药物有益。1.抗PD-(L)1联合抗血管生成Dr. Kalemkerian回顾了联用血管生成靶向药物贝伐珠单抗或多靶点酪氨酸激酶抑制剂（包括仑伐替尼、卡博替尼和司曲替尼）的试验生存数据，以及对比PD-1/VEGF双特异性抗体依沃西单抗和PD-1抗体帕博利珠单抗的HARMONi-2试验数据。Lung-MAP S1800A：在既往接受过抗PD-1/PD-L1治疗的患者中，使用帕博利珠单抗（pembrolizumab）+雷莫芦单抗（ramucirumab）缺乏无进展生存期和缓解率获益，尽管该试验以总生存（OS）为主要终点，且OS获益具有统计学意义。[5]APPLE(WJOG)：该试验发现在化疗中添加抗血管生成贝伐珠单抗没有任何有意义的增益。[6]LEAP-007：结果显示帕博利珠单抗+乐伐替尼（抗血管生成）组合疗效反劣于单药帕博利珠单抗，且毒性更大。[7]SAPPHIRE：这项研究对比了司曲替尼（sitravatinib）+纳武利尤单抗（nivolumab）vs多西他赛单药用于二线治疗，结果显示免疫疗法联合抗血管生成疗法并不能改善结果。[8]HARMONi-2：PD-1/VEGF双特异性抗体依沃西单抗的结果似乎优于PD-1抗体帕博利珠单抗，但对比两个药物的HARMONi-2试验存在需要考量的重要因素，比如III期HARMONi-2缺乏OS数据；帕博利珠单抗单药并不是PD-L1表达1-49%患者真正的标准治疗方法；中位随访时间仍然很短；需等待HARMONi-2研究结果在来自更广泛的地理和种族的患者中得到确认。2.抗PD-(L)1联合抗CTLA-4Dr. Kalemkerian分析了PD-(L)1和抗CTLA-4药物组合的研究结果在非小细胞肺癌和小细胞肺癌中的研究结果。通过从2019~2023年的一系列研究，他发现联合治疗的结果为“无有意义的获益”或“毒性增加”，其中一些研究是双输（lose lose），比如ARCTIC研究。ARCTIC：III期ARCTIC评估了度伐利尤单抗±Tremelimumab对比标准治疗（SoC）三线及以上治疗晚期NSCLC的疗效，根据PD-L1表达情况分为PD-L1 TC≥25％亚组和PD-L1 TC<25％亚组。结果显示PD-L1抑制剂+CTLA-4抑制剂的毒性更大，相比单用度伐利尤单抗无OS获益。[9]CASPIAN：在广泛期小细胞肺癌治疗方面，度伐利尤单抗+Tremelimumab+化疗相比度伐利尤单抗+化疗使毒性发生率增加，OS反而缩短2.5个月（10.4 vs 12.9个月）。[10]目前还有很多失败的ICI联合方案（联合化疗以外的药物），未来还会有更多失败的联合策略出现。那么，双特异性抗体免疫治疗会取代PD-(L)1药物吗？Dr. Kalemkerian的答案是‘不会’，至少现在不会。Dr. Kalemkerian说“至少今天不会”，这与他的辩论对手提出的一个关键概念“时机”相呼应。展望未来我们是根据目前已有研究发现对双特异性抗体做出判断，还是根据未来可能的研究发现做出判断？在演讲中，Dr. Riess着眼于不久的将来，并援引冰球传奇人物Wayne Gretzky的智慧来处理这个问题——滑向冰球将要去的地方，而不是它曾经去过的地方。[11]与之相反，Dr. Kalemkerian秉持"紧盯当下冰球位置"的务实精神，要求业内同道以当前最有效治疗方法为基准来评估新研究数据，在冰球滑向可能错误的角落之前，目光所及之处是正确的冰球。参考文献（上下滑动可查看）1. Parvez A, Choudhary F, Mudgal P, Khan R, Qureshi KA, Farooqi H, Aspatwar A. PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment. Front Immunol. 2023 Dec 1;14:1296341. doi: 10.3389/fimmu.2023.1296341. PMID: 38106415; PMCID: PMC10722272.2. Zhong T, et al. AACR-NCI-EORTC International Conference 2023. Poster #B123, Abstract #35333, Boston, MA, USA3. Zhou C, Chen J, Wu L, et al: Phase 3 study of ivonescimab (AK112) vs pembrolizumab as first-line treatment for PD-L1–positive advanced NSCLC: Primary analysis of HARMONi-2. 2024 World Conference on Lung Cancer. Abstract PL02.04. Presented September 8, 2024.4. Dovedi SJ, Elder MJ, Yang C, Sitnikova SI, Irving L, Hansen A, Hair J, Jones DC, Hasani S, Wang B, Im SA, Tran B, Subramaniam DS, Gainer SD, Vashisht K, Lewis A, Jin X, Kentner S, Mulgrew K, Wang Y, Overstreet MG, Dodgson J, Wu Y, Palazon A, Morrow M, Rainey GJ, Browne GJ, Neal F, Murray TV, Toloczko AD, Dall’Acqua W, Achour I, Freeman DJ, Wilkinson RW, Mazor Y. Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+?Activated T Cells. Cancer Discov. 2021 May;11(5):1100-1117. doi: 10.1158/2159-8290.CD-20-1445. Epub 2021 Jan 8. PMID: 33419761.5. Reckamp KL, Redman MW, Dragnev KH, et al. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A [published correction appears in J Clin Oncol. 2022 Sep 1;40(25):3002. doi: 10.1200/JCO.22.01464.].?J Clin Oncol. 2022;40(21):2295-2306. doi:10.1200/JCO.22.009126. Shiraishi Y, Kishimoto J, Tanaka K, Sugawara S, Daga H, Hirano K, Azuma K, Hataji O, Hayashi H, Tachihara M, Mitsudomi T, Seto T, Nakagawa K, Yamamoto N, Okamoto I. Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 Sep;21(5):472-476. doi: 10.1016/j.cllc.2020.03.010. Epub 2020 Apr 10. PMID: 32381420.7. Yang, James Chih-Hsin et al. Journal of Thoracic Oncology, Volume 19, Issue 6, 941 – 953 Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial8. Borghaei H, de Marinis F, Dumoulin D, Reynolds C, Theelen WSME, Percent I, Gutierrez Calderon V, Johnson ML, Madroszyk-Flandin A, Garon EB, He K, Planchard D, Reck M, Popat S, Herbst RS, Leal TA, Shazer RL, Yan X, Harrigan R, Peters S; SAPPHIRE Investigators. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2024 Jan;35(1):66-76. doi: 10.1016/j.annonc.2023.10.004. Epub 2023 Oct 20. PMID: 37866811.9. Planchard D，et al. ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. Ann Oncol. 2020 May;31(5):609-618. doi: 10.1016/j.annonc.2020.02.006. Epub 2020 Feb 20. PMID: 32201234.10. Paz-Ares L, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022 Apr;7(2):100408. doi: 10.1016/j.esmoop.2022.100408. Epub 2022 Mar 10. PMID: 35279527; PMCID: PMC9161394.11. A common misattribution of a quote that may have come from Wayne Gretzky’s father（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

免疫疗法临床结果临床3期上市批准上市后研究

100 项与 Creatine monohydrate 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Creatine monohydrate	-	DB00148

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肌萎缩侧索硬化	临床3期	美国	Avicena Group, Inc.	2003-06-01
帕金森病	临床3期	-	Avicena LLC	-
亨廷顿舞蹈病	临床2期	美国	The General Hospital Corp.	2005-04-01
腓骨肌萎缩症	临床1期	美国	Avicena Group, Inc.	2006-01-25
肌营养不良	临床1期	美国	Avicena Group, Inc.	2006-01-25
天使综合征	临床前	美国	Rady Children's Hospital-San Diego	2011-12-01
天使综合征	临床前	美国	University of California	2011-12-01
天使综合征	临床前	美国	National Institutes of Health	2011-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04504253 (CTgov)	临床3期	重度抑郁症	18	Creatine monohydrate (Creatine Monohydrate)	獵夢艱鹽顧範齋窪願鑰(淵選選構憲衊襯鬱鹹糧) = 選餘築艱繭夢糧餘餘衊選壓淵襯壓選鬱襯積積 (構遞憲遞遞壓憲鹽構築, 4.2) 更多	-	2024-11-26
				Placebo (Placebo)	獵夢艱鹽顧範齋窪願鑰(淵選選構憲衊襯鬱鹹糧) = 構觸餘繭醖餘簾築醖願選壓淵襯壓選鬱襯積積 (構遞憲遞遞壓憲鹽構築, 6.8) 更多
NCT05329480 (Pubmed)	N/A	多发性内分泌瘤病	-	Creatine	鏇衊積蓋製艱窪願窪選(築築遞鬱窪夢製淵壓蓋) = 觸鑰糧淵夢鏇鑰鏇淵淵鑰選鏇構鑰觸膚膚壓餘 (鑰艱鹹鏇顧壓膚窪築積, 13.4) 更多	积极	2024-10-01
NCT04395183 (CTgov)	临床2期	重度抑郁症	43	placebo matched to 5-HTP+5-Hydroxytryptophan 100 MG (5-HTP + Placebo)	簾餘鑰網糧廠夢願壓範 = 淵鑰鏇蓋範繭憲範齋築糧憲鹽繭夢壓齋壓製鬱 (觸鹽鑰願壓鹽膚壓廠鹹, 衊網範夢鏇艱鏇鑰選廠 ~ 築齋餘壓蓋鬱鏇遞獵壓) 更多	-	2024-07-23
				placebo matched to 5-HTP+Creatine monohydrate (Creatine + Placebo)	簾餘鑰網糧廠夢願壓範 = 齋膚顧夢願餘襯膚顧衊糧憲鹽繭夢壓齋壓製鬱 (觸鹽鑰願壓鹽膚壓廠鹹, 觸構齋遞衊糧構蓋鏇簾 ~ 繭夢獵淵簾鬱鹹憲製鹽) 更多
NCT01502813 (CTgov)	N/A	认知	40	Omega-3 Fatty Acids+Creatine+Citicoline	壓鏇構淵鏇鹽範醖壓築(鹽簾範齋窪構廠憲構構) = 鬱積積襯淵壓鹹齋簾獵獵範觸鹹繭壓網醖鏇範 (壓積簾糧廠衊夢簾衊選, 願鹹鹽齋鏇顧壓遞廠襯 ~ 鏇糧齋壓夢顧鑰鑰襯鏇) 更多	-	2021-04-22
NCT04086381 (Pubmed)	N/A	眼球运动障碍	14	Creatine monohydrate supplementation	廠範膚網憲鑰襯繭壓膚(鹹醖遞廠憲壓膚糧網鏇) = 醖艱蓋繭遞築選艱製遞艱繭構積醖餘蓋顧憲觸 (襯鏇選蓋窪齋顧衊獵窪, -73.06 ~ 10.42) 更多	-	2021-01-18
NCT03350282 (Pubmed \| Nutrition)	N/A	高同种半胱胺酸血症	14	Guanidinoacetic acid with creatine	餘遞壓繭衊鬱廠醖製夢(鹹淵膚夢鑰齋窪願憲廠) = 廠鹽築製襯壓範憲憲糧網蓋窪網壓壓鏇觸醖淵 (膚鹹廠夢淵壓憲鹹網鬱 ) 更多	积极	2019-01-01
				Creatine alone	餘遞壓繭衊鬱廠醖製夢(鹹淵膚夢鑰齋窪願憲廠) = 簾齋築構獵繭夢遞膚構網蓋窪網壓壓鏇觸醖淵 (膚鹹廠夢淵壓憲鹹網鬱 ) 更多
NCT01655030 (Pubmed \| J Neural Transm (Vienna))	N/A	躁郁症	35	Creatine monohydrate 6g daily	簾淵積壓窪遞壓淵衊積(廠獵構顧構簾蓋夢艱鏇) = No clinically relevant physical side-effects were reported or observed 鑰鑰積廠憲築獵簾蓋遞 (選鏇襯鏇網築廠醖鏇範 ) 更多	积极	2018-02-01
				Placebo
NCT02356107 (CTgov)	临床4期	缺氧 \| 重度抑郁症 \| 难治性抑郁症	15	Creatine monohydrate+5-hydroxytryptophan	顧網糧膚遞壓窪糧鏇餘(鹹齋願膚糧醖淵遞顧餘) = 網獵夢艱範憲襯鹽窪鹹窪鏇憲餘衊夢淵醖襯憲 (顧鹹積網製糧淵糧膚壓, 2.5) 更多	-	2018-01-04
NCT01890382 (Pubmed \| J Frailty Aging)	N/A	虚弱综合症	200	Whey protein and creatine co-supplementation	願壓膚網鏇構鬱壓襯糧(淵積鹹鏇鹽齋選願構鑰) = 醖積鑰憲餘壓鑰獵觸鏇範憲網餘構製壓衊願獵 (鏇觸餘襯醖膚糧廠醖範 ) 更多	-	2016-01-01
				Creatine (Whey protein supplementation)	願壓膚網鏇構鬱壓襯糧(淵積鹹鏇鹽齋選願構鑰) = 窪鬱製鬱鑰鹽繭願觸鏇範憲網餘構製壓衊願獵 (鏇觸餘襯醖膚糧廠醖範 ) 更多